Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference
2021年12月21日 - 6:05AM
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the
“Company”), a specialty pharmaceutical company, announced today
that Brian Markison, Chief Executive Officer, James “JD” Schaub,
Chief Operating Officer, and Andrew Einhorn, Chief Financial
Officer, will present virtually at the H.C. Wainwright Bioconnect
Conference as follows:
Date: |
Monday, January 10, 2022 |
On Demand Time: |
7:00AM ET |
Webcast: |
https://journey.ct.events/view/b39a70c0-7058-4a1f-ba97-e18b13918fc7 |
|
|
The presentation will be webcast on-demand and available for 30
days thereafter using the link provided above and via the Company’s
website at www.osmotica.com under the “Investor & News”
section.
About Osmotica Pharmaceuticals plcOsmotica
Pharmaceuticals plc (Nasdaq: OSMT) is a specialty pharmaceutical
company focused on the development and commercialization of
products that target markets with underserved patient populations.
RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary
supporting UPNEEQ®.
Osmotica has operations in the United States and Hungary.
Investor and Media Relations for Osmotica
Pharmaceuticals plcLisa M. WilsonIn-Site Communications,
Inc.T: 212-452-2793E: lwilson@insitecony.com
Osmotica Pharmaceuticals (NASDAQ:OSMT)
過去 株価チャート
から 11 2024 まで 12 2024
Osmotica Pharmaceuticals (NASDAQ:OSMT)
過去 株価チャート
から 12 2023 まで 12 2024
Real-Time news about Osmotica Pharmaceuticals PLC (ナスダック市場): 0 recent articles
その他のニュース記事